Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Paul J. Hampel, MD
Mayo Clinic in Rochester
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Stanford Cancer Institute Palo Alto
Palo Alto, California, United States
Bita Fakhri, MD, MPHNot, yet, recruiting - Mayo Clinic in Rochester
Rochester, Minnesota, United States
Paul J. Hampel, MDRecruiting - Washington University School of Medicine
St Louis, Missouri, United States
Withdrawn
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 5 Jan 2023
- Primary completion
- 22 Feb 2027
- Completion
- 22 Feb 2027
- Last update posted
- 25 Mar 2026
- Registered enrollment
- 27
- Registry id
- NCT05388006
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.